Gapping down
In reaction to disappointing earnings/guidance:
- XENT -19.9% (also announces departure of Lisa Earnhardt as CEO), TXMD -13.2%, HIIQ -11.6%, NLS -11.2%, GSKY -9.4%, ARMK -7.4%, FRAC -6.5%, DNR -6.3%, TACO -6.1%, IAG -5.5%, SYKE -5.4%, RCII -5.3%, PAHC -5%, DF -4.8%, REGN -4.7%, AEIS -4.2%, EMR -3.8%, VCEL -3.8%, KLAC -3.6%, SEAS -3.3%, DFRG -3.3%, MOS -2.6%, BUD -2.6%, IFF -2.3%, GLUU -2%, RP -1.8%, CDEV -1.5%, BHVN -1.5%, INSM -1.5%, BE -1.4%, BHF -1.4%, QGEN -1.4%, GLPI -1.3%, RRTS -1.3%, IVC -1.2%, AMAG -1.2%, OCN -1.2%, RNG -1%
Other news:
- CPRX -37% (after the FDA approved Jacobus Pharmaceutical's Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age)
- TWST -5.5% (announces public offering of 3.0 mln shares of common stock)
- SGMO -4.9% (ahead of earnings on May 8)
- PMT -4.9% (prices offering of 8 mln share of common shares for gross proceeds of $169 mln)
- O -2.4% (prices offering of 11 mln shares of common stock at $69.25 per share)
- UPLD -1.2% (commences 2.75 mln common stock offering)
- YETI -1.2% (files for 9.5 mln share common stock offering by selling shareholders)
- CAT -0.8% (in reaction to comments from USTR Lighthizer confirming that tariffs will rise on Friday)
Analyst comments:
- FLR -2.3% (downgraded to Neutral from Buy at Goldman)
- GDI -1.7% (downgraded to Neutral from Buy at UBS)
- FAST -1.2% (downgraded to Mkt Perform from Outperform at William Blair)
- BA -1.1% (downgraded to Equal Weight from Overweight at Barclays)